Abdel Razik Hussein FARRAG, Hanna Hamdy AHMED, Wafaa Ghoneim SHOUSHA, Rehab Mahmoud HUSSIEN

Potential role of some nutraceuticals in the regression of Alzheimer’s disease in an experimental animal model

Aim: The goal of this study was to evaluate the potential role of some nutraceuticals, coenzyme Q10, vitamin B complex, and lecithin against aluminum-induced neurodegeneration characteristic of Alzheimer’s disease. Materials and methods: Ninety-six male and female Sprague Dawley rats were divided into 2 main groups, namely female and male. Each group was divided into 6 subgroups. Group 1 served as control group. Group 2 was administered AlCl3 for 4 months. Groups 3, 4, 5, and 6 were administered with AlCl3 for 4 months then treated with Coenzyme Q10, vitamin B complex, lecithin, or all in combination for 3 months, respectively. Brain acetylcholinesterase (AChE), Na+/K+- ATPase activities, and vitamin B12, folate, homocysteine (Hcy), lipid peroxidation, glutathione, and plasma nitric oxide (NO) levels were determined. Moreover, histopathological examination of brain tissue was evaluated. Results: Al intoxication caused a significant increase in brain AChE activity, Hcy, lipid peroxidation, and plasma NO levels, while it produced significant decrease in brain Na+/K+-ATPase activity, glutathione, vitamin B12, and folate levels. Moreover, histopathological investigation of the brain of Al intoxicated rats showed marked neurodegeneration and deposition of neurofibrillary tangles. Treatment with the selected nutraceuticals revealed an improvement in the neurological damage induced by AlCl3 as indicated by improvement in most of the biochemical markers and histopathological features. Conclusion: The selected nutraceuticals (Coenzyme Q10, vitamin B complex, lecithin, and their combination) may play a beneficial role in delaying the progression of neurodegenerative disorders. It is noteworthy that the combined therapy revealed more pronounced effect compared to singular treatments with either one of them.

PDF

___

1. Farina M, Lara FS, Brandao R, Jacques R, Rocha JBT. Effects of aluminum sulfate on erythropoiesis in rats. Toxicol Lett 2002;132: 131-39.
2. Kim MS, Lenore S, Clesceri LS. Aluminum exposure: a study of an effect on cellular growth rate. Sci Total Environ 2001; 278:127-35.
3. Levesque L, Mizzen CA, McLachlan DR, Fraser PE. Ligand specific effects on aluminium incorporation and toxicity in neurons and astrocytes. Brain Res 2000; 877: 191-202.
4. Nayak P. Aluminum: Impacts and Disease. Environ Res Sect 2002; 89: 101-15.
5. Flaten TP. Aluminum as a risk factor in Alzheimer’s disease, with emphasis on drinking water. Brain Research Bulletin 2001; 55:187-96.
6. Mattson MP. Pathways towards and away from Alzheimers disease. Nature 2004; 430: 631-39.
7. Exely C. The aluminium-amyloid cascade hypothesis and Alzheimer’s disease. Subcell Biochem 2005; 38: 225-34.
8. Campbell A. Aluminum increases levels of beta-amyloid and ubiquitin in neuroblastoma but not in glioma cells. Proceedings of the Society for Experimental Biology and Medicine 2000;223: 397-402.
9. Bus AI, Huang X, Fairlie DP. The possible origin of free radicals from amyloid beta peptides in Alzheimers disease. Neurobiol Aging 1998; 20: 335-37.
10. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K et al. Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacology and Therapeutics 2007; 113: 154-64.
11.. Babich H, Liebling EJ, Burger RF, Zuckerbraun HL, Schuck AG. Choice of DMEM, formulated with or without pyruvate, plays an important role in assessing the in vitro cytotoxicity of oxidants and prooxidant nutraceuticals. In Vitro Cell Dev Biol Anim 2009; 45: 226-33.
12.. Cornelli U. Antioxidant use in nutraceuticals. Clin Dermatol 2009; 27: 175-94.
13. Morganti P. The photoprotective activity of nutraceuticals. Clin Dermatol 2009; 27: 166-74.
14. Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001; 21: 797-806.
15. Meins W, Muller-Thomsen T, Meier-Baumgartner HP. Subnormal serum vitamin B12 and behavioural and psychological symptoms in Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 15: 415-18.
16. Sruerenburg HJ, Mueller-Thomsen T, Methner A. Vitamin B12 plasma concentrations in Alzheimer disease. Neuro Endocrinol Lett 2004; 25: 176-77.
17. Rodríguez-Martín JL, Qizilbash N, López-Arrieta JM. Thiamine for Alzheimer’s disease. Cochrane Database Syst Rev 2001; 2:CD001498.
18. Chung SY, Moriyama T, Uezu E, Uezu K, Hirata R, Yohena N. Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia. J Nutr 1995; 125: 1484-89.
19. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003; 3: CD0011015.
20. Dave KR, Syal AR, Katyare SS. Effect of long-term aluminum feeding on kinetic attributes of tissue cholinesterases. Brain Res Bull 2002; 58: 225-33.